0001127602-22-012860.txt : 20220502
0001127602-22-012860.hdr.sgml : 20220502
20220502164552
ACCESSION NUMBER: 0001127602-22-012860
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220428
FILED AS OF DATE: 20220502
DATE AS OF CHANGE: 20220502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LANGER ROBERT
CENTRAL INDEX KEY: 0001239757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 22882722
MAIL ADDRESS:
STREET 1: 98 MONTVALE RD
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-28
0001682852
Moderna, Inc.
MRNA
0001239757
LANGER ROBERT
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Common Stock
2022-04-28
4
M
0
703
0
A
11467664
D
Common Stock
14132
I
By: Michael D. Langer Irrevocable Trust u/d/t dated 12/14/95
Common Stock
14132
I
By: Samuel A. Langer Irrevocable Trust u/d/t dated 12/14/95
Common Stock
14132
I
By: Susan K. Langer Irrevocable Trust u/d/t dated 12/14/95
Restricted Stock Units
0
2022-04-28
4
M
0
703
0
D
Common Stock
703
0
D
Stock Option (Right to Buy)
142.52
2022-04-28
4
A
0
5415
0
A
Common Stock
5415
5415
D
Restricted stock units convert into common stock on a one-for-one basis.
The shares subject to this restricted stock unit award vested in full on April 28, 2022.
This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
/s/ Brian Sandstrom, as Attorney-in-Fact
2022-05-02